T-CELL COSTIMULATION BY B7/BB1 INDUCES CD8 T-CELL-DEPENDENT TUMOR REJECTION - AN IMPORTANT ROLE OF B7/BB1 IN THE INDUCTION, RECRUITMENT, AND EFFECTOR FUNCTION OF ANTITUMOR T-CELLS

被引:193
作者
RAMARATHINAM, L [1 ]
CASTLE, M [1 ]
WU, Y [1 ]
LIU, Y [1 ]
机构
[1] NYU MED CTR, KAPLAN COMPREHENS CANC CTR, DEPT PATHOL, HEIDELBERGER DIV IMMUNOL, NEW YORK, NY 10016 USA
关键词
D O I
10.1084/jem.179.4.1205
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A successful antitumor T cell immune response involves induction, recruitment, and effector function of T cells. While B7/BB1 is known as a major costimulatory molecule in the induction of T cell responses, its role in T cell recruitment and effector function is still unclear. In this study, we show that introducing a major costimulatory molecule B7/BB1 into a major histocompatibility complex class II-negative tumor cell line, J558, results in a drastic reduction of its tumorigenicity. The tumor rejection depends on CD8 T cells but not CD4 T cells. However, unlike the previous reports on melanoma cell lines, B7/BB1-transfected J558 cells fail to induce cross-protection against parental J558 cells. The B7/BB1-transfected (J558-B7), but not untransfected J558 cells (J558-Neo) induce a CD8 T cell-dominant inflammatory response, and the T cells isolated from the tumor infiltrating lymphocytes (TIL) are polyclonal in terms of their T cell receptor Vbeta usage. Most surprisingly, the freshly prepared TIL have a potent, CD8 T cell-mediated cytotoxicity on tumor cells without any in vitro stimulation. The cytotoxic T lymphocyte (CTL) activity can be blocked by anti-CD8 monoclonal antibody (mAb). Interestingly, the CTL lyse J558-B7 about 10- to 80-fold more efficiently than untransfected J558-Neo cells. This preferential lysis cannot be attributed to recognition of B7/BB1-derived antigen by the T cells. This finding, together with the lack of the cross-protection between the J558-B7 and J558-Neo, suggests that B7/BB1 can also function at the effector phase of CTL responses. This notion is confirmed by our findings that the lysis of J558-B7 can be blocked by anti-B7 mAbs. Taken together, our results indicate that not only can the B7/BB1 molecule function as a costimulatory molecule at the initiation of immune response, it can also play a major role in T cell recruitment and effector function. This conclusion has significant implications for immunotherapy of tumors.
引用
收藏
页码:1205 / 1214
页数:10
相关论文
共 47 条
[1]  
ALLAN JE, 1987, CURR TOP MICROBIOL, V134, P131
[2]   CD28 INTERACTION WITH B7-COSTIMULATES PRIMARY ALLOGENEIC PROLIFERATIVE RESPONSES AND CYTOTOXICITY MEDIATED BY SMALL, RESTING LYMPHOCYTES-T [J].
AZUMA, M ;
CAYABYAB, M ;
BUCK, D ;
PHILLIPS, JH ;
LANIER, LL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (02) :353-360
[3]  
AZUMA M, 1993, J IMMUNOL, V150, P2091
[4]   CONSTITUTIVE EXPRESSION OF B7 RESTORES IMMUNOGENICITY OF TUMOR-CELLS EXPRESSING TRUNCATED MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II MOLECULES [J].
BASKAR, S ;
OSTRANDROSENBERG, S ;
NABAVI, N ;
NADLER, LM ;
FREEMAN, GJ ;
GLIMCHER, LH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (12) :5687-5690
[5]   THE MHC MOLECULE I-E IS NECESSARY BUT NOT SUFFICIENT FOR THE CLONAL DELETION OF V-BETA-11-BEARING T-CELLS [J].
BILL, J ;
KANAGAWA, O ;
WOODLAND, DL ;
PALMER, E .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 169 (04) :1405-1419
[6]   PHENOTYPIC ANALYSIS OF THE INFLAMMATORY EXUDATE IN MURINE LYMPHOCYTIC CHORIOMENINGITIS [J].
CEREDIG, R ;
ALLAN, JE ;
TABI, Z ;
LYNCH, F ;
DOHERTY, PC .
JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 165 (06) :1539-1551
[7]   COSTIMULATION OF ANTITUMOR IMMUNITY BY THE B7 COUNTERRECEPTOR FOR THE LYMPHOCYTE-T MOLECULES CD28 AND CTLA-4 [J].
CHEN, LP ;
ASHE, S ;
BRADY, WA ;
HELLSTROM, I ;
HELLSTROM, KE ;
LEDBETTER, JA ;
MCGOWAN, P ;
LINSLEY, PS .
CELL, 1992, 71 (07) :1093-1102
[8]  
DIALYNAS DP, 1983, J IMMUNOL, V131, P2445
[9]   HIGH-LEVEL EXPRESSION OF THE PLASMA-CELL ANTIGEN PC-1 ON THE T-CELL SUBSET EXPANDING IN MRL/MPJ-LPR/LPR MICE - DETECTION WITH A XENOGENEIC MONOCLONAL-ANTIBODY AND ALLOANTISERA [J].
DUMONT, FJ ;
HABBERSETT, RC ;
COKER, LZ ;
NICHOLS, EA ;
TREFFINGER, JA .
CELLULAR IMMUNOLOGY, 1985, 96 (02) :327-337
[10]   CAPACITY OF UNPRIMED CD4+ AND CD8+ T-CELLS EXPRESSING V-BETA-11 RECEPTORS TO RESPOND TO I-E ALLOANTIGENS INVIVO [J].
GAO, EK ;
KANAGAWA, O ;
SPRENT, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (06) :1947-1957